ALX 0141

Drug Profile

ALX 0141

Alternative Names: ALX-0141; EDP-406

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Ablynx
  • Developer Ablynx; Eddingpharm
  • Class Proteins
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Postmenopausal osteoporosis
  • Preclinical Bone disorders

Most Recent Events

  • 07 Oct 2016 ALX 0141 is available for licensing (excluding China, Hong Kong, Macau, Thailand) as of 07 Oct 2016. http://www.ablynx.com/
  • 18 Oct 2013 ALX 0141 licensed to Eddingpharm in China, Hong Kong, Macau and Taiwan
  • 01 Mar 2012 ALX 0141 is available for licensing as of 01 Mar 2012 (http://www.ablynx.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top